DNLI Stock Analysis: Buy, Sell, or Hold?
DNLI - Denali Therapeutics Inc. Common Stock
$24.40
-0.42 (-1.69%)
âŧ
5d:
-1.73%
30d:
+7.35%
90d:
+25.84%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When DNLI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: DNLI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: DNLI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: DNLI is currently trading at $24.40, which is considered fair relative to its 30-day fair value range of $23.11 to $25.62.
Technical Outlook: Technically, DNLI is in a strong uptrend. Immediate support is located at $22.63, while resistance sits at $25.74.
Market Sentiment: DNLI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $35.44 (+45.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DNLI is in a strong uptrend. Immediate support is located at $22.63, while resistance sits at $25.74.
Market Sentiment: DNLI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $35.44 (+45.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$23.11 -
$25.62
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.2% below Wall St target ($35.44)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$23.11 -
$25.62
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$22.63
Resistance Level
$25.74
Current Trend
Strong Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.05
Wall Street Target
$35.44
(+45.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 16, 2026 11:57 AM ET
Data refreshes hourly during market hours. Next update: 12:57 PM
Data refreshes hourly during market hours. Next update: 12:57 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNLI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 43 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 67 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 55 HOLD |
|
SMMT
Summit Therapeutics PLC |
STRONG BUY
10 analysts |
$29 | 58 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$101 | 50 HOLD |
